Mineok Chang

Dr. Mineok Chang

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Hak Seung LeeHak Seung Lee
Hak Seung Lee
KPKyung Woo Park
Kyung Woo Park
JKJeehoon Kang
Jeehoon Kang
YKYou-Jeong Ki
You-Jeong Ki
MCMineok Chang
Mineok Chang
HKHyoSoo Kim
HyoSoo Kim
To demonstrate the association of the serum creatinine/serum cystatin C ratio (sarcopenia index, SI) with clinical outcomes including cardiovascular and bleeding risk in older patients who underwent percutaneous coronary intervention (PCI), we analyzed a multicenter nation-wide pooled registry. A total of 1086 older patients (65 years or older) who underwent PCI with second-generation drug-eluting stents (DES) were enrolled. The total population was divided into quartiles according to the SI, stratified by sex. The primary clinical outcomes were major adverse cardiovascular events (MACE, all-cause death, myocardial infarction and target lesion revascularization) and thrombolysis in myocardial infarction major and minor bleeding during a 3-year follow-up period. In the total population, MACE occurred within 3 years in 154 (14.2%) patients. The lowest SI quartile group (Q1) had a significantly higher 3-year MACE rate (Q1 vs. Q2–4; 23.1% vs. 11.2%, p < 0.001), while bleeding event rates were similar between the groups (Q1 vs. Q2–4; 2.6% vs. 2.2%, p = 0.656). The Cox proportional hazard model showed that lower SI is an independent predictor for MACE events (HR 2.23, 95% CI 1.62–3.07, p < 0.001). The SI, a surrogate for the degree of muscle mass, is associated with cardiovascular and non-cardiovascular death, but not with bleeding in older patients who underwent PCI.

4 December 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YKYou-Jeong Ki
You-Jeong Ki
JKJeehoon Kang
Jeehoon Kang
Hak Seung LeeHak Seung Lee
Hak Seung Lee
MCMineok Chang
Mineok Chang
JHJung-Kyu Han
Jung-Kyu Han
HKHyoSoo Kim
HyoSoo Kim
Paravalvular leak (PVL) is an important complication of transcatheter aortic valve implantation (TAVI) and is associated with poor prognosis. We aimed to identify the risk factors for PVL after TAVI including patient (calcium amount or location), device (leakage-proof or not), and procedural (oversizing index (OI)) factors. The primary outcome was mild or greater PVL at 1-month follow-up echocardiography. Overall, 238 patients who underwent TAVI using eight types of valves (Edwards Sapien, Sapien XT, Sapien 3, CoreValve, Evolut R, Evolut PRO, Lotus, and Lotus Edge) were included. The incidence of significant PVL (≥mild PVL) was 24.4%. Although patient factors (calcification of valve) were not predictors of PVL, valve without leakage-proof function (Edwards Sapien, Sapien XT, and CoreValve) was a significant predictor of PVL (adjusted odds ratio, 3.194, 95% CI, 1.620–6.299). Furthermore, OI has a significant protective role against PVL (PVL increased by 45% when OI decreased by 5%). The best cutoff value of OI to predict the absence of PVL was ≥17.6% for the Evolut system and ≥10.2% for the Sapien system. The predictors of PVL after TAVI included factors from the device (valve without leakage-proof function) and procedure (under-sizing). In patients with a high risk of PVL, the procedure should be optimized using valves with leakage-proof function and adequate OI.

25 January 2021 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
HLHak Seung Lee
Hak Seung Lee
JKJeehoon Kang
Jeehoon Kang
KPKyung Woo Park
Kyung Woo Park
YKYou‐Jeong Ki
You‐Jeong Ki
MCMineok Chang
Mineok Chang
HKHyoSoo Kim
HyoSoo Kim

13 May 2025 in European Heart Journal - Digital Health
Verified
Journal Article
Open access
KCKyung Hoon Cho
Kyung Hoon Cho
YJYoung Hoon Ji
Young Hoon Ji
SJSunghoon Joo
Sunghoon Joo
MCMineok Chang
Mineok Chang
SOSeok Oh
Seok Oh
MJMyung Ho Jeong
Myung Ho Jeong
Aims: Rapid myocardial revascularization in patients with acute myocardial infarction (AMI) is essential to improve clinical outcomes. There is still room for improvement in the timely diagnosis of AMI. This study aimed to develop an artificial intelligence (AI) model using electrocardiograms (ECGs) for detecting AMI needing revascularization. Methods and results: A total of 723 389 ECGs from 300 627 patients in the derivation cohort at a single centre between 2013 and 2020, including 5872 patients with AMI (1.95%) who underwent revascularization, were used for model training and internal testing. A transformer-based deep learning model, initially trained on about one million unlabelled ECGs through self-supervised learning, was fine-tuned for AMI detection. The model's final performance was evaluated in the internal test and the external validation set. The external validation was conducted at an independent centre between 2002 and 2020 using 261 429 ECGs from 259 454 patients, including 1095 patients with AMI (0.42%). By integrating self-supervised learning to train the AI model, we enhanced the AMI detection performance, as demonstrated by an increase in the area under the receiver operating characteristic curve (AUROC) from 0.910 (95% CI, 0.904–0.915) to 0.968 (95% CI, 0.965–0.971) in the external validation set. For ST-elevation myocardial infarction and non-ST-elevation myocardial infarction detection, the AUROCs were 0.991 (95% CI, 0.989–0.993) and 0.947 (95% CI, 0.942–0.952) in the external validation set, respectively. Conclusion: This novel ECG-based AI model may be beneficial for the timely identification of patients with AMI needing revascularization.

20 January 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
MPMi hwa Park
Mi hwa Park
MKMincheol Kim
Mincheol Kim
MLMan Jong Lee
Man Jong Lee
AKAh Jin Kim
Ah Jin Kim
KCKyungjae Cho
Kyungjae Cho
JKJung Soo Kim
Jung Soo Kim
Background: Ward patients who experience clinical deterioration are at high risk of mortality. Conventional rapid response systems (RRS) using track-and-trigger protocols have not consistently demonstrated improved outcomes. This study evaluated the impact of an artificial intelligence (AI)-based cardiac arrest prediction model. Methods: This 1-year, prospective, non-randomized interventional trial assigned hospitalized patients with AI-based software as a medical device (AI-SaMD) high-risk alerts to groups based on their subsequent clinical response; those reassessed or treated within 24 h comprised the AI-SaMD-guided cohort, while the remainder formed the usual care cohort. Alerts prompted an optional but not mandatory treatment review. The primary outcome was ward-based cardiac arrest; the secondary outcome was in-hospital mortality. Multivariable regression analysis was used to adjust for potential confounders. Results: Of 35,627 general ward admissions, 2906 triggered an AI-SaMD alert. Among these, 1409 (48.4%) were allocated to the AI-SaMD-guided cohort. The incidence of cardiac arrest significantly decreased from 2.07% to 1.06% (adjusted risk ratio (RR), 0.54; 95% confidence interval (CI), 0.20–0.88; p < 0.01). In-hospital mortality also significantly declined (adjusted RR, 0.65; 95% CI, 0.32–0.98; p < 0.05). Conclusions: AI-SaMD-guided alerts were associated with reductions in cardiac arrest and in-hospital mortality without requiring additional resources, supporting their integration into current clinical workflows to improve patient safety and optimize RRS performance.

25 November 2013 in QJM: An International Journal of Medicine
Verified
Journal Article
Open access
PDF file
MCMineok Chang
Mineok Chang
DMD. Moon
D. Moon
JYJ.- E. Yi
J.- E. Yi
HYH.- J. Youn
H.- J. Youn
DKD.- W. Kim
D.- W. Kim
MCM. Chang
M. Chang
A 41-year-old man presented to the hospital with sudden onset of chest tightness. His past medical history was notable for diagnosis of chronic myeloid leukemia (CML), made at 33 years. He was treated with imatinib, dasatinib and allogeneic peripheral blood stem cell transplant (PBSCT) with HLA mismatched, unrelated donor and he was still in complete hematologic response.